Here’s the latest!
Apple in Secret Effort for Diabetes Treatment, according to the CNBC report, 12 April 2017. This could be exciting!
Apple has had a team of biomedical engineers working on a secret initiative to develop non-invasive glucose sensors, originally envisioned by the late Steve Jobs, hoping to be the first to track blood sugar levels accurately without piercing the skin.
Verily, the life-sciences unit of Alphabet (Google), is working on glucose sensors including a smart contact lens that would measure sugar levels through the eye.
- Apple has a secret team working on the holy grail for treating diabetes
- What is the smart lens program?
- Apple is testing a noninvasive blood glucose monitor
Insulin is 90 Years Old and Costs More Than Ever … Why? As reported on TheDiabetesSite.com, the patent for insulin was sold to the University of Toronto in the early 1920s, over ninety years ago, for … are you ready? … $1 … yup, ONE DOLLAR!
Many would say that these changes have been for the better, toward a safer, more effective administration and reception of the insulin. BUT each change has resulted in the extension of patents — patents that belong to brand-name players in the pharmaceutical industry.
The extension of patents means that, even though insulin for diabetes is over 90 years old, it cannot become a “generic drug.”
According to HealthSmart “A generic drug is a chemically equivalent, lower-cost version of a brand-name drug, costing 30-80% less! A brand-name drug and its generic version must have the same active ingredient, dosage, safety, strength, usage directions, quality, performance and intended use.”
Thirty to 80 percent lower cost … THAT IS SIGNIFICANT!